loading...| Preferred Name | Etoricoxib | |
| Synonyms |
5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine Arcoxia ETORICOXIB Etoricoxib L-791456 MK-0663 |
|
| Definitions |
A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C52188 |
|
| CAS_Registry |
202409-33-4 |
|
| CHEBI_ID |
CHEBI:6339 |
|
| Chemical_Formula |
C18H15ClN2O2S |
|
| code |
C52188 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
FDA GDC |
|
| DEFINITION |
A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. |
|
| FDA_UNII_Code |
WRX4NFY03R |
|
| FULL_SYN |
5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine Arcoxia ETORICOXIB Etoricoxib L-791456 MK-0663 |
|
| Is_Value_For_GDC_Property | ||
| label |
Etoricoxib |
|
| Legacy Concept Name |
Etoricoxib |
|
| Maps_To |
Etoricoxib |
|
| NCI_Drug_Dictionary_ID |
462092 |
|
| PDQ_Closed_Trial_Search_ID |
462092 |
|
| PDQ_Open_Trial_Search_ID |
462092 |
|
| Preferred_Name |
Etoricoxib |
|
| prefixIRI |
Thesaurus:C52188 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0972314 |
|
| subClassOf |